Blog

VHH antibodies are single-domain antibody fragments derived from the unique heavy-chain-only antibodies (HCAbs) of camelids, including alpacas, llamas, and camels.

As of the end of 2025, 21 ADCs have been approved globally, with four new approvals added in 2025 alone. Antibody-drug conjugates (ADCs) are a class of targeted biotherapeutics that combine the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs.

Antibody engineering has progressed beyond classical depletion and neutralization strategies to encompass diverse modalities that engage immune tolerance, tissue-specific immunomodulation, and tumor immunity.

The 2025 Antibody Engineering & Therapeutics US (AET US) conference was held in San Diego on December 14-17, 2025. The event theme was "Accelerating Tomorrow's Antibody Therapeutics Today".

The 2025 mAbTalk Symposium by The Chinese Antibody Society was held in San Deigo, CA, on December 14, 2025. The event focused on “Novel Modalities in the Frontier of Antibody Therapeutics”, with 100+ attendees and 15+ sponsors in attendance.

On Friday, December 12th, 2025, Biointron celebrated the end of the year with a spectacular annual year-end networking party at Boston Marriott Newton in Boston. Bringing together industry professionals, partners, and clients, the event celebrated Biointron’s achievements and hosted two exciting guest speaker presentations.

Overview of affinity maturation. DOI: 10.1016/j.coviro.2015.04.002I. The Biological Basis of Affinity MaturationAffinity maturation is the central process through which antibodies evolve to bind their antigens with higher specificity and affinity. In vivo, this process occurs in the germinal c

Antibody thermal stability refers to the ability of an antibody to retain its structural conformation and binding function when exposed to elevated temperatures. It includes both chemical and physical aspects of protein integrity. Thermal stability is especially critical in therapeutic and diagnostic applications where antibodies must remain effective during manufacturing, shipping, storage, and use.

Expression system selection plays a central role in determining the success of VHH antibody development. Factors such as expression yield, folding efficiency, post-translational modifications (PTMs), scalability, and cost all influence the suitability of a given system for research, diagnostic, or therapeutic use.

PEGS Europe2025 conference was held inLisbon, Portugal, fromNovember11to November13, 2025.The Proteinand Antibody Engineering Summithad focusedsessions onbispecifics,multispecifics, machine learning, and novel target engagement

Explore microfluidic screening for function-first antibody discovery. Identify active antibodies early using single-cell droplet technology and native IgG secretion.

The Society for Immunotherapy of Cancer (SITC) 2025 conference was held in National Harbor, Maryland, from November 5 to November 9, 2025. Forty years ago, breakthroughs in recombinant DNA, monoclonal antibody technology, and tumor immunology laid the groundwork for cancer research. At SITC, experts and emerging investigators across biotech, academia, government, and pharma come to advance immuno-oncology and improve patient outcomes.